Cellectar Biosciences Inc. (CLRB)
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/rWaldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/rWaldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak clinical signals • Minimal impact anticipated **Sentiment:** Neutral (50%) **Content type:** Clinical